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ABSTRACT
Activation of NF-B-dependent transcription repre-
sents an important hallmark of inflammation. While
the acute inflammatory response is per se beneficial,
it can become deleterious if its spatial and tempo-
ral profile is not tightly controlled. Classically, NF-
B activity is limited by cytoplasmic retention of the
NF-B dimer through binding to inhibitory IB pro-
teins. However, increasing evidence suggests that
NF-B activity can also be efficiently contained by
direct ubiquitination of NF-B subunits. Here, we
identify the HECT-domain ubiquitin ligase HERC3 as
novel negative regulator of NF-B activity. We find
that HERC3 restricts NF-B nuclear import and DNA
binding without affecting IB degradation. Instead
HERC3 indirectly binds to the NF-B RelA subunit af-
ter liberation from IB inhibitor leading to its ubiq-
uitination and protein destabilization. Remarkably,
the regulation of RelA activity by HERC3 is indepen-
dent of its inherent ubiquitin ligase activity. Rather,
we show that HERC3 and RelA are part of a multi-
protein complex containing the proteasome as well
as the ubiquitin-like protein ubiquilin-1 (UBQLN1).
We present evidence that HERC3 and UBQLN1 pro-
vide a link between NF-B RelA and the 26S pro-
teasome, thereby facilitating RelA protein degrada-
tion. Our findings establish HERC3 as novel candi-
date regulating the inflammatory response initiated
by NF-B.
INTRODUCTION
Activation of the NF-B transcription factor is critically in-
volved in executing inflammatory and immune reactions.
On a molecular level, under resting conditions, NF-B
proteins are rendered inactive by association with IB
and IB-related inhibitor proteins, which retains the tran-
scription factor in the cytoplasm (1). Upon stimulation,
proteolysis of IB is induced (2), which allows NF-B
to enter the nucleus, where it initiates the transcription
of different classes of genes, such as growth factors, pro-
and anti-inflammatory cytokines and adhesion molecules
(3). As important as its activation is the down-regulation
of NF-B signaling once the inflammation or immune
challenge is overcome. If the shutdown mechanism fails,
maintenance of tissue homeostasis is jeopardized and re-
maining NF-B activity can drive cancer and inflamma-
tory pathology (4). Termination of the NF-B response is
mainly achieved by re-association with its inhibitor IB,
whose synthesis itself is dependent on NF-B (5). Newly
synthesized IB enters the nucleus, where it binds to
NF-B, which leads to removal from its cognate DNA
binding sites (6). Although IB undoubtedly functions
as main repressor of NF-B, more recent findings indi-
cate that NF-B-dependent transcription can also be ef-
ficiently restricted through alternative mechanisms involv-
ing degradative and non-degradative deactivation of NF-
B subunits by ubiquitin targeting (7–12). Several ubiqui-
tin ligases that target the NF-B dimer have been identi-
fied. SOCS-1, part of a multi-subunit RING ubiquitin lig-
ase, acts in concert with COMMD1 and GCN5 to promote
poly-ubiquitination and degradation ofRelA,RelB and p52
(13,14). The nuclear ubiquitin ligase PDLIM2, which con-
tains a LIM domain structurally similar to RING domains,
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was found to terminate NF-B activity in myeloid cells
through poly-ubiquitination and degradation of RelA (12).
More recently, the peroxisome proliferator activated recep-
tor gamma (PPAR ) (8) and the tumor suppressor pro-
tein ING4 (15) were added to the growing list of NF-B-
targeting ubiquitin ligases.
HERC3 represents a HECT domain ubiquitin ligase
belonging to the class of human homologous to E6AP
carboxyl-terminus (HECT) and regulator of chromosome
condensation (RCC)-1 containing subfamily (16). Apart
from reports that HERC3 can form thioester bonds with
ubiquitin, a prerequisite for functional HECT domain
ubiquitin ligases (17,18) and that it itself undergoes ubiq-
uitination and proteasomal degradation (17), it remains
largely unstudied. Recently we found that HERC3 inter-
acts with the ubiquitin-like proteins hPLIC1/UBQLN1 and
hPLIC2/UBQLN2 (19), however a functional connection
remains to be established.
Here, we show that HERC3 negatively regulates NF-B
signaling by enhancing RelA subunit degradation.While its
ubiquitin ligase activity is dispensable for this function, we
find that HERC3 together with UBQLN1 facilitates RelA
degradation by serving as bridge to the 26S proteasome.
MATERIALS AND METHODS
Antibodies
The following primary antibodies were used in this study:
-actin (AC-15; Sigma-Aldrich) c-myc (9E10), flag (M2;
Agilent Technologies), hemagglutinin (HA; 12CA5; Roche
Applied Science), HERC3 (HPA039170; Sigma-Aldrich),
IB (6A920, Imgenex), myc (71D10; Cell Signaling),
PSMA4 (MCP34; Enzo Life Sciences), PSMC2 (MSS1–
104; Enzo Life Sciences), PSMD4 (D17E4; Cell Signaling),
RelA (C-20 and F-6; Santa Cruz Biotechnology), UBQLN1
(D3T7F; Cell Signaling), mono- and polyubiquitin (ubi-1;
Life Technologies), lysine-48 ubiquitin (Apu2; EMDMilli-
pore) and lysine-63 ubiquitin (D7A11; Cell Signaling).
Cell culture and reagents
Human embryonic kidney (HEK) 293T cells, obtained
from the American Type Culture Collection (ATCC), and
RelA−/− 3T3 fibroblasts, kindly provided by Dr Amer A.
Beg, were maintained in DMEM (MediaTech) containing
10% (v/v) fetal bovine serum (FBS; Atlanta Biologicals).
Bovine aortic endothelial cells (BAEC) and human umbil-
ical vein endothelial cells (HUVEC) were purchased from
VecTechnologies and cultured in DMEM supplemented
with 10% (v/v) FBS or MCDB131 medium (VecTechnolo-
gies), respectively. All cells were cultured in a humidi-
fied atmosphere containing 5% CO2. Plasmid transfections
into HEK293T and BAEC were unless otherwise stated
achieved with Lipofectamine 2000 (Life Technologies) at
about 85 and 65%, respectively, as observed by green flu-
orescent protein co-expression. Where indicated, cells were
treated with MG132 (50 M; EMDMillipore), leptomycin
B (LMB; 20 ng/ml; Enzo Life Sciences) or human recombi-
nant tumor necrosis factor (TNF; 10 ng/ml; Life Technolo-
gies).
Plasmid constructs
pCMV-myc-HERC3, pcDNA3-flag-HERC3, pcDNA3-
HA-IB, pcDNA3 expressing myc-tagged RelA, as well
as pcDNA3-his-ubiquitin have been described (7,19,20).
pCMV-myc-HERC3 CA was obtained by mutation of the
active site cysteine residue at position 1018 to alanine. To
construct pCMV-myc-HERC3 HECT (aa 1–845) and
RLD (aa 1–367), pCMV-myc-HERC3 full length was cut
with SmaI-NotI and BglII-NotI, respectively, and overhang
ends of the residual vector backbone were filled with T4
DNA polymerase before re-ligation. The un-blunted BglII-
NotI fragment was in parallel cloned into pCMV-myc
(Clontech) to retrieve pCMV-myc-HERC3 RLD (aa
368–1050). pCMV-flag-HERC3 and pcDNA3-flag-RelA
were obtained by exchanging the myc cassette with a
flag cassette through pre-annealed primers harboring the
classic flag amino acid (aa) sequence DYKDDDDK.
pcDNA3-myc RelA lysine to arginine (K195R, K315R
and K195/315R) mutants were generated by site-directed
mutagenesis (Agilent Technologies) according to manufac-
turer’s instructions. The NF-B luciferase reporter gene
constructs 3x B-, IL8-, ICAM1-, IB- and MHC-I-luc
were described elsewhere (20–22). pCMV2-flag-IKK2
K44M (23) (Addgene plasmid 11104), flag-UBQLN1
(Addgene plasmid 8663) (24), pHM830 (GFP-LacZ) and
pHM840 (GFP-SV40 NLS-LacZ) (25) (Addgene plasmids
20702 and 20701) were provided by Drs Anjana Rao,
Peter M. Howley and Thomas Stamminger, respectively.
All plasmid constructs were verified by automated DNA
sequencing.
Co-immunoprecipitation assay in cells
Cells were collected and lysed in RIPA buffer (50 mM
Tris-HCl pH8, 150 mM NaCl, 1 mM EDTA pH8, 1%
(v/v) Igepal CA-630, 0.5% (v/v) sodiumdeoxycholate, 0.1%
(v/v) SDS, 20 mM N-ethylmaleimide, protease inhibitors).
Whole cell extracts were cleared by centrifugation, 1/20
was kept for expression control, and rest of supernatants
was incubated with respective antibodies coupled to protein
A-sepharose or agarose matrices. Immunoprecipitates were
washed thrice with lysis buffer, and eluted from beads by
addition of SDS-sample buffer and boiling for 10 min. Pro-
teins were resolved on SDS-PAGE and detected byWestern
Blotting with respective antibodies.
In vitro translation and co-immunoprecipitation assay
Plasmids containingmyc-RelA, flag-HERC3 andHA-IB
were linearized to enable efficient transcription/translation
via T7 RNA polymerase. Coupled in vitro transcrip-
tion and translation was carried out with the TNT T7
Coupled Wheat Germ Extract System (Promega) accord-
ing to manufacturer’s instructions. Flag-UBQLN1 was
transcribed/translated from a circular plasmid with SP6
RNA polymerase (New England Biolabs). For immunopre-
cipitation, reactions were mixed after translation was fin-
ished and 1/10 was removed for input control. RIPA buffer
was added and IB and HERC3 were pulled down with
HA and flag agarose beads, respectively. Precipitates were
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washed 3 times withRIPAbuffer, eluted from beads by boil-
ing in SDS-sample buffer, resolved on SDS-PAGE and de-
tected by Western Blotting with appropriate antibodies.
Ubiquitination assay under native conditions
HEK293T cells transfected with his-ubiquitin and myc-
RelA with or without myc-HERC3 were harvested in RIPA
buffer. Presence of ubiquitinated RelA was determined af-
ter precipitation of total RelA with RelA-coupled protein
A-sepharose, and Western Blotting with respective anti-
ubiquitin antibodies.
Denaturating ubiquitination assay
HEK293T or BAEC were transfected with histidine-tagged
ubiquitin as well as expression constructs for RelA and
HERC3. Histidine–ubiquitin was precipitated under de-
naturating conditions (6 M guanidine hydrochloride) via
a nickel-NTA-coupled agarose resin (Qiagen) from either
whole cell extracts or subcellular fractions as previously de-
scribed (19). Ubiquitinated RelA was detected after pull
down by Western Blotting with RelA-specific antibody.
RelA stability in HUVEC
HUVEC were transfected with siRNAs targeting human
Herc3 and Ubqln1, or a non-targeting control. Three days
post-transfection, cells were either left untreated or stimu-
lated with TNF for 0.5 and 6 h, after which they were har-
vested in RIPA buffer. Protein levels of RelA, HERC3 and
UBQLN1 were assessed by Western Blotting with respec-
tive antibodies. -actin served as a loading control.
Metabolic pulse chase labeling
HUVEC, transfected HEK293T or BAEC cells were
washed twice and then incubated for 30 min in labeling
medium (methionine/cysteine-free DMEM supplemented
with 2 mM L-glutamine and 0.5% (v/v) dialyzed FBS).
Cells were subsequently pulsed with 400 Ci/ml [35S]-
methionine (Perkin Elmer) for 1 h (in case of HUVEC
in presence of TNF), washed twice with labeling medium
and further incubated with complete DMEM + 10% (v/v)
FBS and 2 mM L-methionine/2 mM L-cysteine for indi-
cated times. The proteasome inhibitorMG132 (50M)was
added for chase time span where indicated. Upon harvest-
ing, cells were washed in ice-cold PBS and RelA was pulled
down by immunoprecipitation from total cell lysates (50
mM Tris-HCl pH8, 150 mM NaCl, 1 mM EDTA pH8, 1%
(v/v) Igepal CA-630, 0.5% (v/v) sodiumdeoxycholate, 0.1%
(v/v) SDS, protease inhibitors). Precipitates were resolved
by SDS-PAGE, gels were dried and exposed to a phosphor
screen (GE Healthcare Life Sciences) over night prior to
analysis on a Phosphoimager (Typhoon Trio, GE Health-
care Life Sciences).
Identification of ubiquitinated residues by nanoLC-ESI-
MS/MS analysis
HEK293T cells were transfected with histidine-tagged
ubiquitin, myc-RelA and myc-HERC3. Cell lysates were
subjected to Ni-NTA pull-down, SDS-PAGE and SYPRO
Ruby (Molecular Probes) stain. Gel bands in the range
of 80–150 kDa were excised, treated with trypsin and re-
sulting peptides were extracted as reported previously (26).
Ubiquitin-conjugated RelA residues were determined by
nanoLC-ESI-MS/MS analysis as described in detail else-
where (7).
Identification of HERC3–RelA interaction partners by
nanoLC-MS/MS
Flag-HERC3 in presence of myc-RelA was precipitated
from transfected HEK293T cells in RIPA buffer (50 mM
Tris-HCl pH8, 150 mMNaCl, 1 mMEDTA pH8, 1% (v/v)
Igepal CA-630, 0.5% (v/v) sodiumdeoxycholate, 0.1% (v/v)
SDS, protease inhibitors) with flag-specific antibody con-
jugated to agarose matrix. Precipitation with IgG isotype
control was used to identify non-specific hits. The precipi-
tate was eluted from the matrix by competition with 3xflag
peptide (Sigma) and samples were filtered through 0.45 m
filter units (Spin-X;Corning) to remove residual beads. Flag
peptides were removed by Zeba spin desalting columns with
7K MWCO (Thermo Fisher Scientific) following vendor’s
recommended protocol. Flag peptide-free samples were col-
lected for subsequent in-solution digestion. Samples were
reduced with 10 mM TCEP at 56◦C for 45 min, alkylated
with 10 mM iodoacetamide for 1 h at room temperature
in the dark, and precipitated with a 6-fold volume of cold
acetone overnight at −20◦C. After washing the pellet twice
with cold acetone, samples were reconstituted in 45 l 100
mM TEAB pH8.5 and digested by incubating with 300 ng
trypsin (Promega) at 37◦C for 16 h. Digests were then de-
salted using solid phase extraction (SPE) on Sep-Pak Car-
tridges (Waters) and the eluted tryptic peptides were evapo-
rated to dryness before analysis. Protein identifications were
conducted by nanoLC-MS/MS analysis as described previ-
ously (7). All MS and MS/MS raw spectra files were con-
verted to MGF files by Proteome Discoverer 1.4 (Thermo
Fisher Scientific) for subsequent database search using in-
house license Mascot Daemon (version 2.3, Matrix Sci-
ence) against Human RefSeq database downloaded from
NCBInr. The database search was performed with two-
missed cleavage sites by trypsin allowed. The peptide tol-
erance was set to 10 ppm and MS/MS tolerance was set to
0.8 Da. A fixed carbamidomethyl modification of cysteine,
variable modifications on methionine oxidation and deami-
dation of asparagine/glutamine were set. Only significant
scores for the peptides defined byMascot probability at 99%
CI greater than ‘identity’ and peptide expectation value less
than 0.05were considered for the peptide identification. The
final protein list contains only proteins, of which at least two
distinct peptides were identified meeting the above criteria.
Luciferase reporter gene assays
For RelA-induced reporter activity, RelA−/− 3T3 or BAEC
were grown in 12-well plates, and unless otherwise stated
in the figure legend, exposed to 400 ng of DNA (200 ng
of reporter plasmid, 20 ng of p65 wt or mutant expression
plasmid, 140 ng of control or HERC3 vectors, and 40 ng
of cytomegalovirus/-galactosidase (CMV--gal) plasmid)
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and 1.6 l of Lipofectamine (Life Technologies) in DMEM
without serum for 6 h. Medium was exchanged with com-
pleteDMEM+10% (v/v) FBS, and cells were allowed to re-
cover for 40 h. For TNF-induced activity, BAECwere trans-
fected in 12-well plates with 600 ng DNA (300 ng reporter
plasmid, 40 ng CMV--gal plasmid and 260 ng of control
or HERC3 vectors) and 1.8l Lipofectamine inDMEMno
serum for 5 h.Mediumwas replaced with complete DMEM
+ 10% (v/v) FBS. After 24 h, TNFwas added for 16 h. Cells
were lysed in 1x passive lysis buffer (Promega) and super-
natants were assayed for luciferase and -galactosidase ac-
tivity as described (22). For detection of AP-1 activity, cells
were transfected with 200 ngAP-1-Luc reporter plasmid to-
gether with 20 ng pFC-MEKK (both from Agilent Tech-
nologies), 140 ng HERC3 vector and 40 ng of respiratory
syncytial virus/-galactosidase (RSV--gal) plasmid.
Small interference RNA (siRNA) knock down
HUVEC were seeded on 0.2% gelatin-coated plates and
grown overnight in antibiotic-free medium. Introduction of
siRNA into HUVEC was performed with Oligofectamine
(Life Technologies) according to manufacturer’s instruc-
tions. Cells were assayed 72 h after transfection. The siRNA
sequence for knock down of human HERC3 was 5′- GGA
GUGAUUGAACAGAAGAUU-3′. Non-targeting con-
trol and UBQLN siRNA was purchased from Dharma-
con (siGENOMEcontrol siRNA#1 and SMARTpoolON-
TARGET plus human UBQLN1 siRNA, respectively).
Immunofluorescence
For determination of nuclear RelA presence, BAEC cells
were seeded on glass-cover-slips and transfected with con-
trol vector or myc-HERC3. For assessment of GFP-LacZ
localization, either GFP-LacZ or GFP-NLS-LacZ was co-
transfected with control vector or myc-HERC3. Cells were
either left untreated or stimulated with TNF/LMB for 30
min and 1 h, followed by fixation with 4% paraformalde-
hyde and permeabilization with 0.5% (v/v) Triton X100
in 1xPBS. RelA and HERC3 were visualized by stain-
ing with mouse monoclonal RelA and rabbit polyclonal
myc primary, followed by Alexa568 anti-mouse IgG and
Alexa488 anti-rabbit IgG secondary antibodies (all Molec-
ular Probes), respectively. GFP was detected by direct
green fluorescence. 4′,6-diamidino-2-phenylindole (DAPI)
was used as nuclear reference. Subcellular distribution of
RelA and HERC3 was analyzed using a Nikon Eclipse
TE2000 microscope equipped with a 40x objective. Pictures
were acquired with a charge-coupled device using identical
acquisition parameters.
Gene expression analysis
RNAwas isolated from control-, RelA- andRelA/HERC3-
transfected BAEC or from control, HERC3 and UBQLN1
siRNA-transfected, untreated or TNF-treated HUVEC
with the RNeasy Plus Kit (Qiagen). Real-time quantita-
tive PCR (qPCR) was carried out as described previously
(20). For BAEC, expression levels were calculated rela-
tive to control-transfected cells, which were set to 1. For
HUVEC, expression levels in un-stimulated, control and
HERC3/UBQLN1 siRNA-treated cells were set to 1, and
fold induction for TNF-treated groups was calculated. Se-
quences of primer pairs used for amplification of human
genes were: Icam1 5′-CCA AGA GGA AGG AGC AAG
ACT-3′ (forward), 5′-CCA ATA GGC AGC AAG TTT
CAG-3′ (reverse); Vcam1 5′-CAT GTA GTG TCA TGG
GCT GTG-3′ (forward), 5′-CTC AAA ACT CAC AGG
GCTCAG-3′ (reverse); Sele 5′-TTCCAAGCAAAGGTG
AAG AGA-3′ (forward), 5′-CAG CTG TCG AAA CAC
TGTGAA-3′ (reverse); Hprt 5′-TTCTGTGGCCATCTG
CTT AGT-3′ (forward), 5′-GCC CAA AGG GAA CTG
ATA GTC-3′ (reverse).
Electrophoretic mobility shift assay (EMSA)
Whole cell extracts were obtained from transfected BAEC
by lysis in buffer containing 50 mM HEPES.NaOH pH7,
250 mM NaCl, 5 mM EDTA, 0.1% (v/v) Igepal CA-
630, protease inhibitor tablets (Roche Applied Science).
Five micrograms of cleared lysates were incubated for 30
min at room temperature with 60 000 cpm of double-
stranded purified  -32P ATP (Perkin Elmer)-labeled Ig 
light chain enhancer oligonucleotide (5′-AGT TGA GGG
ACT TTC CCA GGC-3′). For competition, either non-
labeled sense oligonucleotide (co Ig B) or non-labeled
scrambled oligonucleotide (5′-ACA GTA TCA AAG GCT
CAC ATG-3′) (co sc Ig B) was added. For the super-shift,
complexes were incubated for 1 h on ice with 1 g of mouse
monoclonal p65 antibody (clone F-6; Santa Cruz Biotech-
nology). Protein–DNA complexes were separated on 5%
Tris/glycine/EDTA poly-acrylamide gels, bands were visu-
alized by autoradiography and band intensities were quan-
tified.
Blue native polyacrylamide gel electrophoresis (BN-PAGE)
HEK293T cells were transfected with flag-RelA and/or
myc- or flag-HERC3 and extracts were obtained through ly-
sis with modified RIPA buffer (50 mM Tris-HCl pH8, 150
mM NaCl, 1 mM EDTA pH8, 1% (v/v) Igepal CA-630,
0.5% (v/v) sodium-deoxycholate, 0.1% (v/v) SDS, 20 mM
N-ethylmaleimide, protease inhibitors). RelA and HERC3
were precipitated with myc- or flag-coupled agarose beads,
and bound proteins were eluted from matrices in blue na-
tive buffer (20 mM Bis/Tris, 20 mM NaCl, 1 mM EDTA
pH8, 10% (v/v) glycerol, 0.1% (v/v) Igepal CA-630, 20 mM
N-ethylmaleimide, protease inhibitors) with respective pep-
tides (3xflag peptide or myc peptide, both Sigma). Lysates
were purified from residual beads by centrifugation through
0.45 m cellulose acetate filter columns and loaded on Na-
tivePAGE Novex 3–12% Bis/Tris protein gels (Life Tech-
nologies). BN-PAGE was executed according to a previ-
ously published protocol (27). Molecular weight of proteins
was indicated by NativeMark unstained protein standard
(Life Technologies).
Size-exclusion chromatography (SEC)
Protein precipitates from transfected HEK293T cells were
obtained as described under BN-PAGE, except that elu-
tion was performed in modified RIPA buffer. A 300 l
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sample was injected onto an equilibrated Sephacryl S-300
HiLoad 16/60 column (GE Healthcare) and run was exe-
cuted at a rate of 500 l/min in 50 mM Tris-HCl pH7.5,
150 mMNaCl, 1 mM phenylmethylsulfonyl fluoride, 1 mM
DTT, 0.1% (v/v) Triton X100. Forty-two x 1 ml fractions
were collected after one column volume had passed. A mix
of thyroglobulin, aldolase and ovalbumin with calculated
molecular masses (Mr) of 6.69 × 105, 1.58 × 105 and 4.4 ×
104, respectively, was used as molecular weight marker. Pro-
teins were precipitated with 12% (v/v) TCA and 5% (v/v)
sodium-deoxycholate, and all fractions were separated on
7% SDS-PAGE.
Statistical analysis
Comparisons between two groups were statistically evalu-
ated by the Student t test. Comparisons between multiple
groups were performed with 1-way ANOVA followed by
Bonferroni post hoc test. Differences were considered sig-
nificant at P < 0.05.
RESULTS
HERC3 negatively regulates NF-B transcriptional activity
In addition to its canonical regulation by inhibitor IB,
NF-B activity is also altered by post-translational modi-
fications at the level of the transcription factor dimer (28).
Using a 3x B luciferase reporter system we found that co-
expression of the ubiquitin ligase HERC3 leads to signif-
icant repression of RelA-induced NF-B reporter activity
in a dose-dependent manner in BAEC as well as in RelA
knock out fibroblasts (RelA−/− 3T3) (Figure 1A). HERC3
did not negatively influence the activity of the transcription
factor AP-1 implying a specific effect on NF-B (Supple-
mentary Figure S2). HERC3 comparably reduced NF-B-
dependent luciferase production from differentNF-B con-
sensus sites (Figure 1B), indicating an upstream rather than
promoter site-specific effect of HERC3. HERC3 not only
influenced RelA-triggered NF-B activation, but also sig-
nificantly attenuated TNF-induced reporter activity in en-
dothelial cells (Figure 1C). Finally, we tested the impact
of HERC3 on endogenous NF-B-regulated gene expres-
sion in BAEC. Production of Icam1-, Vcam1-, Sele- and
IκBα-mRNA was induced by transiently transfecting cells
with RelA. Co-transfection of HERC3 decreased the RelA-
dependent induction of gene expression on all genes tested
(Icam1 andVcam1 *P< 0.05; Sele p= 0.11; IκBα p= 0.06)
(Figure 1D). In summary, we show here that the ubiquitin
ligase HERC3 represses RelA- and TNF-stimulatedNF-B
transcriptional activity.
HERC3 limits NF-B nuclear presence and DNA-binding
Nuclear translocation is critical for activation of NF-B-
dependent transcription (29), hence we next observed RelA
subcellular localization in absence and presence of HERC3
co-expression. Indeed, HERC3 significantly reduced RelA
nuclear presence in TNF-stimulated BAEC (Figure 2A).
This effect was still apparent after addition of the nuclear
export inhibitor leptomycin B (LMB), suggesting that re-
duced nuclear RelA levels are not a result of accelerated nu-
clear export. Next we assessed whether HERC3 has a gen-
eral impact on the nuclear import machinery or rather af-
fects NF-B specifically. RelA nuclear translocation is gov-
erned by a classical monopartite nuclear localization se-
quence (NLS) (30). Hence we tested HERC3 effects on the
nuclear presence of GFP-LacZ fused to a similar proto-
typic monopartite NLS derived from the SV40 large T-
antigen, which would be taken up into the nucleus by the
same mechanism as RelA (25). However, co-transfection of
HERC3 did not alter nuclear translocation of GFP-NLS-
LacZ (Figure 2B), suggesting that HERC3 does not gen-
erally impair nuclear import. To verify that nuclear NF-
B was reduced, we measured RelA DNA-binding levels in
BAEC transfected with RelA with or without HERC3 by
electrophoretic mobility shift assay (EMSA). While RelA
expression markedly induced RelA DNA-binding as com-
pared to the control, co-expression of HERC3 attenuated
this effect (Figure 2C), indicating that the reduced nuclear
translocation of RelA in presence of HERC3 is indeed re-
flective of less DNA-bound NF-B. The observed signal
was eliminated with a non-labeled Ig B oligonucleotide
(co) and super-shifted with RelA antibody, ensuring its NF-
B specificity (Figure 2D).
HERC3 does not effect IB degradation
Next we set out to determine the mechanism by which
HERC3 limits NF-B nuclear appearance. Given the exclu-
sive presence of HERC3 in the cytoplasm (Figure 2A) and
(17,19), it is highly likely that HERC3 exerts its effect on
RelA before it enters the nucleus. Themain regulator ofNF-
B subcellular localization is IB, which is removed in the
cytoplasm upon stimulation by ubiquitin-dependent prote-
olysis (31,32). To test whether HERC3 is suppressing IB
degradation to inhibit NF-B nuclear translocation, we ob-
served IB protein levels with andwithoutHERC3 expres-
sion after TNF stimulation. As shown in Figure 3A, IB
levels were decreased regardless of HERC3 over-expression,
indicating that HERC3 does not interfere with IB degra-
dation. In contrast, over-expression of dominant-negative
IKK2 (23) and pre-treatment of cells with MG132 pro-
teasome inhibitor totally blocked IB removal. Addition-
ally, unlike MG132 treatment HERC3 expression did not
promote accumulation of ubiquitinated IB (Figure 3B),
which likely would be observed if IB degradation was in-
hibited. Taken together, the reduced RelA nuclear translo-
cation in presence of HERC3 cannot be attributed to stabi-
lization of IB.
HERC3 binds to NF-B RelA and promotes its ubiquitina-
tion
HERC3 constitutes a putative HECT-domain ubiquitin
ligase (17) and therefore may directly induce RelA ubiq-
uitination, which in turn might affect NF-B subcellu-
lar localization and/or protein stability. We found by co-
immunoprecipitation assays that HERC3 binds to RelA
(Figure 4A, B), a prerequisite for promoting RelA ubiquiti-
nation. To assess whether HERC3 is able to regulate ubiqui-
tination of RelA we co-expressed the two proteins together
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Figure 1. HERC3 suppresses NF-B transcriptional activity. (A) BAEC andRelA−/− 3T3 were transfected with B-luciferase reporter (200 ng) and CMV-
-galactosidase control (40 ng) plasmids together with RelA (20 ng) and increasing amounts of HERC3 (BAEC: 80, 160 and 320 ng; RelA−/- 3T3: 35, 70
and 140 ng). Luciferase activities were measured 3 days after transfection and normalized to -galactosidase activities. Bars represent mean + SEM (n =
9, derived from 3 independent experiments). RelA-induced reporter activity was set to 100 and activity of all other data sets was calculated relative to this
value. (B) Assay was carried out in RelA−/− 3T3, transfected as in (A) with different NF-B decameric consensus binding sites and constant amounts of
HERC3. Sites were derived from the human IL8, ICAM1, IB andMHC class I enhancer sequences. (C) BAEC were transfected with reporter plasmids,
control vector or HERC3, and either left untreated or 2 days later stimulated with TNF for 16 h. Bars represent mean + SEM (n = 12, derived from four
independent experiments). TNF-induced reporter activity without HERC3 co-expression was set to 100. (D) BAEC transiently transfected with control,
RelA or RelA plus HERC3 were harvested, RNA was isolated and expression levels of endogenous Icam1, Vcam1, Sele and IκBα were evaluated by qRT-
PCR. Expression levels of control-transfected cells were set to 1, and relative induction for all other experimental groups was calculated. Bars represent
mean + SEM (n = 5, derived from 5 independent experiments). In all experiments appropriate protein expression was monitored by Western Blotting (see
Supplementary Figure S1A–D). Data were considered significant at *P < 0.05. RLU, relative luciferase units.
with histidine-tagged ubiquitin and performed an ubiquiti-
nation assay under denaturing conditions.While no ubiqui-
tinated RelA was detected when RelA was expressed alone,
HERC3 co-expression readily induced RelA ubiquitination
(Figure 4C). Further, we detected a notable increase in en-
dogenous RelA ubiquitination in presence of HERC3 in
TNF-stimulated BAEC (Figure 4D). Interestingly, we find
that presence of IB significantly reduces HERC3 bind-
ing to RelA (Supplementary Figure S3A) and as a conse-
quence abates HERC3-mediated RelA ubiquitination (Sup-
plementary Figure S3B), supporting the interpretation that
HERC3 exerts its effect on NF-B after its liberation from
IB inhibitor.
Confirmative of RelA ubiquitination in presence of
HERC3 we identified two ubiquitinated RelA lysine (K)
residues, K195 and K315, with HERC3 co-expression by
tandem mass spectrometry (nanoLC-ESI-MS/MS) (Sup-
plementary Figure S4A). Interestingly the same residues
among others were shown to be modified with ubiquitin be-
fore (7,33). Confirming the MS data, substitution of lysine
to arginine at positions 195 and 315 markedly decreased
RelA ubiquitination levels in presence of HERC3 (Sup-
plementary Figure S4B). However, mutation of the same
lysines only minimally reverted HERC3 effects on RelA
transcriptional activity (Supplementary Figure S4C). Since
residual ubiquitination is detected with the RelA double
KRmutant (Supplementary Figure S4B), it is likely that ad-
ditional RelA lysines might be targeted by HERC3. In sum-
mary, our data support HERC3 as novel protein mediating
NF-B RelA ubiquitination after liberation from IB at a
minimum of two lysine acceptor sites.
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Figure 2. HERC3 reduces NF-BDNA-binding by limiting its nuclear import. (A) BAECwere transfected with control vector or myc-HERC3, stimulated
for 0, 0.5 or 1 h with TNF or TNF/LMB and processed for immunofluorescence. Nuclei were stained with DAPI. Bar represents 10 m. The graph shows
ratios of cytosolic and nuclear fluorescence obtained by automatic quantification of RelA compared to DAPI staining (n = 61–147 cells, derived from
2–3 experiments). Values N/C > 1 indicate predominantly nuclear RelA. (B) Subcellular localization of GFP-LacZ harboring a SV40-derived nuclear
localization sequence (NLS) was tested in absence and presence of myc-HERC3 in BAEC. GFP-LacZ, not containing an active NLS, was used as control.
DAPI staining served as nuclear reference. Size bar = 10 m. Data from 18–33 cells for each condition, derived from two independent experiments,
were quantified. Percent of nuclear GFP staining was: for GFP-LacZ –HERC3 0 ± 0; +HERC3 0.12 ± 0.02, and for GFP-SV40NLS-LacZ –HERC3
100 ± 0; +HERC3 100 ± 0. (C) RelA DNA-binding in absence and presence of HERC3 was observed by electrophoretic mobility shift assay (EMSA).
Total cell extracts from transfected BAEC were incubated with double-stranded purified  -32P ATP-labeled Ig light chain enhancer oligonucleotide.
Protein–DNA complexes were separated on 5% Tris/glycine/EDTA-PAGE, bands were visualized by autoradiography and results from three experiments
were quantified. Equal RelA protein expression with and without HERC3 was ensured by parallel observation of protein levels by Western Blotting
(see Supplementary Figure S1E). (D) RelA binding was verified by competition with either non-labeled sense oligonucleotide (co Ig B) or non-labeled
scrambled oligonucleotide (co sc Ig B), and by super-shift with RelA antibody. Experiments were performed in triplicates. The arrows in (C) and (D)
indicate the specific NF-B band. Values were considered significant at *P < 0.05. h, hours.
HERC3 induces K48-linked RelA ubiquitination and protein
destabilization
We have shown that HERC3 mediates the ubiquitination of
RelA, which could potentially impact its protein stability.
Ubiquitin has seven lysine residues (K6, K11, K27, K29,
K33, K48, and K63). Any one of them can be conjugated
to another ubiquitin resulting in the formation of polyubiq-
uitin chains of different linkages. While K48 chains mainly
target proteins for degradation by the 26S proteasome,K63-
linked ubiquitin chains influence target proteins in a non-
degradative manner (34). By using antibodies detecting ex-
clusively K48- or K63-linked ubiquitin molecules we evalu-
ated the type of ubiquitin chain conjugated to immunopre-
cipitatedRelA in presence ofHERC3. Stainingwas only ob-
served with K48-specific antibody (Figure 5A), indicating
that HERC3 might target RelA for proteasomal degrada-
tion. Therefore, we next tested whether HERC3 influences
RelA protein stability. As shown in Figure 5B and C, RelA
protein was significantly less stable in presence of HERC3
in HEK293T and endothelial cells, resulting in a more than
50% reduction in RelA protein half-life. This effect was par-
tially reverted by administration of a proteasome inhibitor
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Figure 3. HERC3 has no effect on IB degradation. (A) IB turnover was monitored in HEK293T cells transfected with empty vector, myc-HERC3 or
flag-dnIKK2 after stimulation with 10 ng/ml TNF for 0, 20 or 60 min. Where indicated cells were pre-treated with 50 MMG132. Presence of transfected
proteins was verified by immunoblotting with myc- or flag-specific antibodies. (B) HEK293T cells were transfected with HA-IB together with either
empty vector or myc-HERC3. Cells were treated with 10 ng/ml TNF for 20 min and where indicated pre-treated for 3 h with 50 M MG132. IB was
pulled down from cell lysates with HA-coupled agarose and its ubiquitination was assessed by detection with an anti-ubiquitin antibody. All experiments
were carried out in triplicates. HC, heavy chain; IB, immunoblot; IP, immunoprecipitation; min, minutes.
(Figure 5C, black bars). Taken together, our data so far sug-
gest thatHERC3mediatesRelA ubiquitination to induce its
degradation before it can enter the nucleus.
HERC3 effects on RelA-dependent transcription and ubiqui-
tination are independent of its catalytic domains
Small HERC proteins contain two potential catalytic do-
mains, the amino-terminal RCC1-like domain (RLD) and
the carboxyl-terminal HECT domain. While ubiquitin
transfer is generally attributed to theHECTdomain, for the
transfer of the ubiquitin-like molecule ISG15 by HERC5,
e.g. both HECT and RLD domains are required (35). To
determine the domains needed for HERC3-mediated NF-
B transcriptional repression and ubiquitination we manu-
factured HERC3 truncation mutants lacking parts of the
RLD or HECT domains (Figure 6A). As shown in Fig-
ure 6B, RelA-dependent transcriptionwas still efficiently re-
pressed by HERC3 mutants carrying an inactive or trun-
cated HECT domain (C1018A or HECT) or missing
RLD domain (RLD). Solely a mutant lacking everything
but the RLD domain (RLD) was unable to suppress NF-
B transcription. Correspondingly, ubiquitination of RelA
was apparent with all tested HERC3 mutants except the
RLD domain alone (Figure 6C). These data indicate that
HERC3 mediates RelA ubiquitination independently of its
catalytic domains. While HERC3 is needed for RelA ubiq-
uitination, it may not actively transfer ubiquitin to NF-B.
SinceHECTdomain proteins need to directly bind their tar-
gets in order to transfer ubiquitin (36), we tested interaction
of in vitro translatedHERC3 andRelA. Supporting the idea
that HERC3 is not directly ubiquitinating RelA, we found
that while HERC3 and RelA interact in cells (Figure 4A,
B), they do not bind to each other in vitro (Supplementary
Figure S5A).
RelA and HERC3 co-sediment at high-molecular weight
(MW) under native conditions
Since HERC3 is not directly involved in ubiquitination of
RelA, we hypothesized that HERC3 functions as a scaffold-
ing protein that facilitates the interaction of RelA and other
proteins involved in ubiquitination or degradation pro-
cesses. Beginning to assess this possibility, we immunopre-
cipitatedHERC3 andRelA eitherwhen transfected alone or
together under native conditions and examined their size by
blue native polyacrylamide gel electrophoresis (BN-PAGE;
Figure 6D) and size-exclusion chromatography (SEC; Fig-
ure 6E). NF-BRelA was located in slowmigrating protein
bands (Figure 6D, lanes 1 and 2) and higher MW fractions
(Figure 6E, first two rows) with and without HERC3, indi-
cating that it is part of a larger protein complex regardless of
HERC3 presence. Similarly, HERC3migrated/fractionated
at highMWwhen not bound toRelA (Figure 6D, lane 3 and
Figure 6E, third row). Interestingly, co-expression led to a
shift of both proteins to even higherMW fractions, suggest-
ing a change in RelA-containing complexes with HERC3,
and vice versa (Figure 6D, lane 2 and Figure 6E, second
and fourth row). In summary, we find native HERC3 and
RelA proteins associated with high MW fractions, indicat-
ing multimerization and/or presence of other proteins.
HERC3/RelA associate with the 26S proteasome and the
ubiquitin-like protein UBQLN1
To reveal proteins bound to HERC3 and RelA we per-
formed LC-MS/MS analysis of control and HERC3 pre-
cipitates from RelA/HERC3-transfected cells. While not
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Figure 4. HERC3 interacts with RelA and mediates its ubiquitination. (A) RelA was precipitated with RelA antibody from total HEK293T cell lysates
transfected with myc-RelA and myc-HERC3. RelA and HERC3 co-precipitation was assessed by Western Blotting with anti-myc antibody. (B) HEK293T
cells were transfected with HA-RelA and myc-HERC3. HERC3 was pulled down from cell lysates with myc-specific antibody and RelA was detected in
the precipitate with anti-RelA antibody. (C) HEK293T were transfected with myc-RelA, his-ubiquitin and myc-HERC3. Ubiquitinated RelA was detected
by pull down of his-ubiquitin under denaturing conditions, followed by Western Blotting with RelA-specific antibody. (D) BAEC were transfected with
his-ubiquitin and myc-HERC3. After 24 h cells were treated with TNF for 30 min and assay was performed as described in (C). All experiments were
carried out in triplicates. IB, immunoblot; IP, immunoprecipitation.
present in the control pull down, we found a considerable
number of proteasomal subunits precipitated with HERC3,
suggesting a specific association with HERC3 and possibly
with RelA (listed in Figure 7A). To confirm the interac-
tion of HERC3/RelA with the proteasome we performed
co-immunoprecipitation assays with various proteasomal
subunits found bymass spectrometry. The 19S ATPase sub-
unit PSMC2 and the 20S core subunit PSMA4 were pulled
down with HERC3 (Figure 7B). We also found HERC3
co-precipitation with the 19S non-ATPase subunit PSMD4
(Figure 7C), further confirming the data obtained by LC-
MS/MS.Notably,HERC3 binding to proteasomal subunits
was detected regardless of RelA presence, while RelA when
expressed alone was unable to efficiently bind the protea-
some (Figure 7B, C).
In addition to proteasomal proteins, LC-MS/MS de-
tected UBQLN1, a protein that was previously found to in-
teract with HERC3 (19) and the proteasome (24) (listed in
Figure 7A). A pull down assay withUBQLN1 not only con-
firmed the interaction of UBQLN1 with HERC3, but also
found associated RelA and proteasomal subunit PSMC2
(Figure 7D). In summary, we identifyUBQLN1 and the 26S
proteasome as binding partners of HERC3/RelA.
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Figure 5. HERC3 mediates RelA K48 ubiquitination and protein destabilization. (A) His-ubiquitin, myc-RelA, with or without myc-HERC3 were tran-
siently introduced into HEK293T cells. RelA was precipitated from whole cell lysates with RelA-specific antibody and the nature of RelA ubiquitination
was examined byWestern Blotting with anti-ubiquitin antibodies recognizing total, K48 orK63 ubiquitin, respectively. (B) HEK293T cells were transfected
with myc-RelA with or without myc-HERC3. Twenty four hours after transfection, cells were pulse-labeled with [35S]-methionine for 1 h and chased for
0, 2, 4 and 8 h. RelA was precipitated from total cell extracts with myc-affinity agarose, and protein levels were detected by autoradiography. (C) RelA
was precipitated from transfected BAEC total cell extracts after pulse-labeling with [35S]-methionine for 1 h and chasing for 0 and 8 h. Protein levels in
precipitates were assessed by separation on SDS-PAGE and autoradiography. Average percent protein remaining before and after chase is indicated. All
experiments were carried out at least in triplicates. h, hours; IB, immunoblot; IP, immunoprecipitation.
HERC3 and UBQLN1 regulate NF-B activity by promot-
ing RelA degradation by the 26S proteasome
Our data so far suggest that HERC3 reduces NF-B tran-
scriptional activity by binding to the proteasome and deliv-
ering RelA for degradation (Figures 1, 4 and 6). UBQLN1
was previously shown to regulate ubiquitin-mediated pro-
teasomal proteolysis (24,37). To test the role of UBQLN1
in HERC3-mediated RelA degradation, we knocked down
UBQLN1 protein and assessed HERC3 binding to RelA
and the proteasome. While depletion of UBQLN1 had
no effect on HERC3 binding to the proteasome, it re-
duced HERC3 binding to RelA (Figure 8A), a finding es-
sentially reproduced when RelA was pulled down (Fig-
ure 8B). Interestingly, in addition we detected less protea-
some bound to RelA without UBQLN1 (Figure 8B), in-
dicating that UBQLN1 is not only required for efficient
RelA binding to HERC3, but also for tethering it to the
proteasome. To assess whether the observed decrease in
HERC3-RelA-proteasome interaction with UBQLN1 de-
pletion has any effect on RelA protein degradation, we
performed pulse chase analyses in presence and absence
of UBQLN1. As seen before, addition of HERC3 in pres-
ence of UBQLN1 significantly decreased RelA protein sta-
bility (Figure 8C). However, RelA levels partly recovered
when UBQLN1 was depleted (Figure 8C), suggesting that
UBQLN1 is needed for HERC3-mediated RelA degrada-
tion. To test whether endogenous RelA was regulated by
HERC3 and/or UBQLN1, we studied RelA protein lev-
els in endothelial cells after siRNA mediated knock down
of HERC3 and UBQLN1. RelA was analyzed in metabol-
ically labeled HUVEC transfected with siRNA and treated
with TNF for 7 h to induce NF-B activity. As expected
RelA protein was markedly reduced in control siRNA cells
(Figure 8D), reflecting a high protein turn over after NF-
B stimulation. HERC3 and UBQLN1 knock down were
able to slightly stabilize RelA under these conditions. Re-
markably, knock down of both HERC3 and UBQLN1 at
the same time potentiated the rescue of RelA protein lev-
els (Figure 8D), suggesting an additive effect. We also ob-
served RelA levels in presence and absence of HERC3 and
UBQLN1 in HUVEC with and without TNF treatment. In
line with pulse chase data we found that knock down of
HERC3 and UBQLN1 increased RelA levels in untreated
as well as TNF-treated cells (Figure 8E). To investigate
whether the stabilization of RelA byHERC3 andUBQLN1
depletion affects NF-B transcription factor activity we
tested the expression ofNF-B-dependent genes after 6 and
16 h TNF stimulation in control and HERC3/UBQLN1
siRNA-treatedHUVEC. In concordance withRelA protein
stability data we find that knock down of either HERC3 or
UBQLN1 leads to a notable increase in NF-B transcrip-
tional activity at 6 h TNF stimulation (Icam1: si-Herc3 P
= 0.65, si-Ubqln1 P = 0.40; Vcam1: si-Herc3 p = 0.12, si-
Ubqln1 *P< 0.05; Sele: si-Herc3 P= 0.59, si-Ubqln1 *P<
0.05) (Figure 8F). Again, knock down of both proteins am-
plified this effect (Icam1: P= 0.24; Vcam1: *P< 0.05; Sele:
*P < 0.05) (Figure 8F). Sixteen hours TNF stimulation led
to similar results (Icam1: si-Herc3 p = 0.41, si-Ubqln1 P
= 0.45, si-Herc3+si-Ubqln1 P = 0.41; Vcam1: si-Herc3 P
= 0.20, si-Ubqln1 *P < 0.05, si-Herc3 + si-Ubqln1 *P <
0.05; Sele: si-Herc3 P = 0.48, si-Ubqln1 P = 0.09, si-Herc3
+ si-Ubqln1 P = 0.07). In conclusion, we show here that
HERC3 and UBQLN1 regulate the turn over of RelA pro-
tein, thereby altering NF-B transcriptional profiles.
DISCUSSION
We identify the ubiquitin ligase HERC3 as novel neg-
ative regulator of NF-B-dependent transcription.
HERC3 achieves this regulation by mediating RelA sub-
unit ubiquitination and destabilization, leading to less
nuclear NF-B. So far all identified ubiquitin ligases
involved in NF-B RelA ubiquitination, including the
COMMD1/SOCS1/GCN5 complex, ING4, PPAR and
PDLIM2, are predominantly nuclear proteins and hence
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Figure 6. HERC3 affects RelA ubiquitination independently of its catalytic domains as part of a larger molecular weight complex. (A) Schematic rep-
resentation of HERC3 constructs used in (B and C). (B) Transcriptional activity of RelA was examined in presence of different HERC3 constructs as
described in Figure 1A. Bars represent mean + SEM (n = 9–18, derived from 3–6 independent experiments). Values were significant at *P < 0.05. (C)
HEK293T cells were transfected with his-ubiquitin, myc-RelA and indicated myc-HERC3 wild type, mutant or truncation constructs. Ubiquitinated RelA
was pulled down with Ni-agarose beads bound to his-tagged ubiquitin and detected in immunoblotting with a RelA-specific antibody. (D) HEK293T cells
were transfected with flag-RelA alone, flag-RelA and myc-HERC3 or flag-HERC3 alone. Lysates were subjected to precipitation with flag-agarose beads,
followed by flag-peptide elution. Eluates were loaded on 3–12% Native Bis-Tris Gels and separated by Blue Native Polyacrylamide Gel Electrophoresis
(BN-PAGE). (E) HEK293T cell transfection, lysate precipitation and elution were performed as outlined in (D). Eluates were loaded on a Sephacryl S-300
HiPrep 16/60 column for size exclusion chromatography (SEC). Thyroglobulin, aldolase and ovalbumin with calculated relative molecular masses (Mr)
of 669, 158 and 44, respectively, served as molecular weight indication. All experiments were carried out in triplicates. aa, amino acids; CA, cysteine to
alanine; ev, empty vector; FR, fraction; IB, immunoblot; IP, immunoprecipitation; Mr, relative molecular mass; RLU, relative luciferase units; V0, column
void volume; wt, wild type.
act on nuclear RelA (8,12–15,38). HERC3 on the contrary
is a cytoplasmic protein (Figure 2 and (17,19)) that affects
NF-B before it enters the nucleus. Interestingly, HERC3
binding and subsequent RelA ubiquitination are inhibited
by IB (Supplementary Figure S3), suggesting that it
targets NF-B after liberation from or in absence of its
inhibitor. NF-B regulatory proteins that influence NF-B
fate in the spatial window between IB removal and nuclear
translocation are rare. One example known to date is the
tumor suppressor Sef, which after stimulus-induced IB
elimination continues to inhibit NF-B nuclear import and
activity by binding to p50 (39). This mechanism is believed
to counterbalance and modulate the extent of the NF-B
response, a process also conceivable for HERC3. There is
another interesting parallel between Sef and HERC3. Like
Sef (39–41), HERC3 co-localizes with endomembranes
(17,19). When visualized by immuno-fluorescence HERC3
resembles a fine punctuate staining especially in perinuclear
regions. Whether HERC3 together with RelA also localizes
to endocytic vesicles remains to be established. Until then
it cannot be excluded that associated endomembranes play
some role in the HERC3-driven retention of NF-B in the
cytoplasm. Interestingly the identified RelA/HERC3 inter-
action partner UBQLN1 resides not only at proteasomes,
but has also been found associated with the endocytic
pathway (42,43). Further investigation will be necessary to
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Figure 7. HERC3/RelA associate with the ubiquitin-like protein UBQLN1 and the 26S proteasome. (A) List of ubiquitination/degradation-associated
proteins found byMS/MSanalysis to bind toHERC3/RelA. (B) HEK293T cells transfected with indicated constructs were lysed and immunoprecipitation
was performed with myc-specific antibody to pull down HERC3. RelA, PSMC2 and PSMA4 co-association was detected with specific antibodies recog-
nizing these proteins. (C) HEK293T cells were transfected with control, myc-RelA, myc-HERC3 or myc-RelA/myc-HERC3 together. The endogenous
proteasomal subunit PSMD4 was precipitated with PSMD4 antibody and association of RelA and HERC3 was tested in Western Blotting with respective
antibodies. (D) HA-RelA, flag-tagged UBQLN1 and myc-HERC3 were introduced into HEK293T cells. Association of HERC3 and RelA, as well as the
proteasomal subunit PSMC2 with UBQLN1 was tested by immunoprecipitation of UBQLN1 with flag-beads, followed by Western Blot detection. All
experiments were performed 3 times. The asterisks mark the heavy chain detected by Western Blotting after immunoprecipitation. IB, immunoblot; IP,
immunoprecipitation.
clarify whether endocytic vesicles are involved in HERC3
and UBQLN1 regulation of RelA, possibly by extending
its cytosolic retention, where it becomes a substrate for the
proteasome.
Unlike Sef, which suppresses NF-B nuclear levels solely
by cytoplasmic sequestration,HERC3mediates its ubiquiti-
nation and degradation.AlthoughHERC3 is equippedwith
a functional HECT domain containing a catalytically active
cysteine residue embedded in a characteristic 4-amino acid
motif (44), our data indicate that HERC3 intrinsic ligase
activity is not required for RelA ubiquitination. Even cat-
alytically inactive HERC3 mutants efficiently induce RelA
ubiquitination (Figure 6C). HECT domain ubiquitin lig-
ases need to directly bind their targets to execute their
function, therefore, we also assessed HERC3 direct binding
to RelA with cell free in vitro binding assays. In contrast
to in vivo binding studies (Figure 4A, B) these assays re-
sulted in no detectable interaction between the two proteins
(Supplementary Figure S5A). These data together with the
ubiquitination assay strongly suggest that another uniden-
tified ligase must act on RelA in presence of HERC3. Al-
though HECT domain ubiquitin ligases contrary to most
RING domain ubiquitin ligases are traditionally known to
act as monomers, the large HERC family member HERC2
was shown to serve as an adaptor protein for the assem-
bly of a multi-ubiquitin ligase complex independently of its
ubiquitin ligase activity (45). There, binding of HERC2 to
RNF8/RNF168 ubiquitin ligases facilitated Ubc13 recruit-
ment and production of K63-linked ubiquitin chains, which
tethered repair factors like p53BP1, RAP80 and BRCA1 to
DNAdamage sites (45). To identify the ubiquitin ligase that
is actually responsible for RelA ubiquitination in presence
of HERC3 we performed mass spectrometry analyses of
HERC3-associated proteins.However, we did not reveal any
ligase associated with HERC3 in presence of RelA, suggest-
ing that it might either be of very low abundance and there-
fore hard to detect by MS analysis or HERC3 indirectly ac-
tivates a RelA-targeting ligase without physically binding to
it. In the latter case a mass spectrometry approach identify-
ing RelA- instead of HERC3-bound proteins would poten-
tially be useful in future studies to reveal the identity of the
acting ligase.
Our analyses of HERC3 and RelA precipitates under
non-denaturing conditions indicate that HERC3 and RelA
are part of aMWcomplex larger than 1000 kDa (Figure 6D,
E). Assuming that the complex does not consist of HERC3
and RelA multimers, we predicted that other proteins are
likely to be present. Although we could not detect an ubiq-
uitin ligase, mass-spectrometry analysis of HERC3-binding
proteins in presence of RelA revealed components of the
 at 20801 Instituto G
ulbenkian de CiÃ¯Â¿Â½ncia on December 16, 2015
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
Nucleic Acids Research, 2015, Vol. 43, No. 20 9901
Figure 8. HERC3 and UBQLN1 conjointly affect NF-B activity by linking RelA to the proteasome and promoting its degradation. (A) UBQLN1
expression was knocked down by siRNA transfection into HEK293T cells. At the same time myc-HERC3 and HA-RelA were introduced and interaction
between these two proteins was studied by co-immunoprecipitation approach. Association of endogenous proteasomal subunits PSMC2 and PSMA4 was
also tested. The asterisks point out the antibody heavy chains detected by Western Blotting after pull down. (B) HEK293T were transfected with siRNA
targeting UBQLN1, myc-HERC3 and myc-RelA. Binding of proteins to RelA was examined by pull down with anti-RelA antibody and detection of
HERC3 and PSMC2 by Western Blotting. (C) Stability of RelA protein in presence of HERC3 and absence of UBQLN1 was determined in HEK293T by
metabolic labeling as described in Figure 5B. Results from 4 independent experiments were quantified. Average percent of protein before and after chase is
noted on top of the respective graph columns. (D) Endogenous RelA protein stability was assessed in HUVEC exposed to siRNA targeting HERC3 and/or
UBQLN1.Non-targeting siRNAwas used as control. HUVECwere incubated in [35S]-methionine-containing growthmedium for 2 h on day 3 after siRNA
exposure. Pulse mediumwas removed and cells were left in culture for another 7 h in normal growthmedium substituted with 10 ng/ml TNF. HUVECwere
harvested and RelA was precipitated from total cell extracts with RelA-specific antibody. Data from four experiments were plotted on a graph. Average
percent protein remaining before and after chase is indicated. (E) HUVEC transfected with non-targeting control or Herc3/Ubqln1-targeting siRNAs
were stimulated with 10 ng/ml TNF for 0, 0.5 and 6 h. Protein levels of endogenous RelA, HERC3, UBQLN1 and -actin were determined. Shown blots
are representative of 2 independent experiments. (F) mRNA expression of three NF-B-regulated genes Icam1, Vcam1 and Sele was examined in siRNA-
treated HUVEC. Three days after siRNA exposure NF-B-dependent transcription was stimulated with TNF for 6 and 16 h. RNA was isolated and gene
expression was assessed by qRT-PCR. HERC3 and UBQLN1 knock down efficiency was tested in un-stimulated cells and plotted in the first two panels.
Data were normalized to each group and represent mean +SEM from 5–9 independent experiments. Values were considered significant at *P < 0.05. IB,
immunoblot; IP, immunoprecipitation; si, small interfering RNA.
26S proteasome, which could total up to 2000 kDa (46). In-
terestingly, even when expressed individually, HERC3 and
RelA are barely detected at monomeric sizes of 115 and 65
kDa, respectively. Minor parts of RelA are found around
100 kDa, which may reflect homo- or heterodimers with
other NF-B proteins (p50, cRel, RelB). The vast major-
ity of RelA protein, however, is detected within two molec-
ular weight peaks around 600–1000 kDa (Figure 6D, E).
This might represent its association with IKK complexes,
which have been shown to reach a size of approximately
900 kDa (23), paired with other NF-B-associated factors,
like IB, p105 or p50. HERC3 expressed alone is found
starting at a molecular weight of 600 kDa, suggesting that
HERC3 like RelA is primarily found in multi-protein com-
 at 20801 Instituto G
ulbenkian de CiÃ¯Â¿Â½ncia on December 16, 2015
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
9902 Nucleic Acids Research, 2015, Vol. 43, No. 20
plexes. Although it would be undoubtedly interesting to as-
sess the protein composition of these individual complexes,
we did not pursue this endeavor for this study.
HERC3 is a poorly characterized protein. Apart from its
cytoplasmic, vesicle-associated localization and suggested
involvement in ubiquitination (by virtue of the presence of
a HECT domain) it has been shown to interact with two
proteins, UBQLN1 and UBQLN2 (19), however, the func-
tional impact of this interaction remained elusive. Interest-
ingly, we again found UBQLN1 in the current MS analy-
sis as HERC3/RelA-interacting protein. UBQLN proteins
contain one ubiquitin-associated (UBA) and one ubiquitin-
like (UBL) domain, which have been previously shown to
associate with ubiquitinated proteins, the ubiquitin ligases
HERC3, TRCP and E6AP and the proteasome (19,24,47).
The ability of UBQLNs to interact with substrates, as well
as components of the ubiquitination and degradation ma-
chineries puts it into a prime spot for regulation of these
processes. However, whether UBQLNs stimulate or inhibit
degradation of proteasomal targets has been controver-
sial. While on the one hand it has been reported that
UBQLNs cause inhibition of ubiquitin-dependent protea-
somal degradation (24), it has also been shown that they en-
hance degradation of ubiquitinated protein substrates (37).
The underlying cause for this discrepancy is not known.
One possible explanation could be that UBQLNs specifi-
cally interfere with degradation of some substrates, while
they promote the degradation of others. This might be regu-
lated at the level of the ubiquitin ligase or at the proteasome
itself. Our model supports a degradation-enhancing role of
UBQLN1 for NF-B, as its knock down rescues HERC3-
induced RelA destabilization (Figure 8C). Although we
show that UBQLN1 binds the proteasome in presence of
HERC3 and RelA (Figure 7D), the regulation of RelA sta-
bility by UBQLN1 may only be partly dependent on its
proteasome binding activity. Rather our data suggest that
UBQLN1 strengthens the binding of HERC3 to RelA (Fig-
ure 8A, B), which is important to deliver RelA to the pro-
teasome. The weakened binding between RelA andHERC3
in absence of UBQLN1 is consistent and leads to effects on
RelA stability and NF-B transcriptional activity, however
the detected changes aremodest. To test whetherUBQLN1,
HERC3 and RelA form a ternary complex via direct inter-
actions we assessed their binding to each other in vitro. As
already suspected from the in vivo data, we found no de-
tectable interaction between the three proteins (Supplemen-
tary Figure S5B). Therefore, it seems likely that additional
proteins are present in the HERC3/UBQLN1/proteasome
complex and future studies will be necessary to further ad-
dress the involvement of currently unidentified players. The
more pronounced effect of HERC3-UBQLN1 double ver-
sus each single knock down onRelA stability and transcrip-
tional activity indicates that the two proteins are not posi-
tioned to affect NF-B in a linear fashion. Instead, HERC3
andUBQLN1may act in concert to strengthenRelA associ-
ation with the proteasome, thereby altering its degradation
profile and as a result its activity.
We show that HERC3 mediates ubiquitination of RelA
on two distinct lysine residues, K195 and K315 (Supple-
mentary Figure S4). Interestingly, the same sites were found
to be ubiquitinated before in our studies and also by oth-
ers. Previously, we detected the ubiquitination of RelAK62,
K123 and K315 in response to proteasomal inhibition (7).
Similarly, Li et al. discovered the ubiquitination of RelA
after proteasomal blockade on seven lysines, among them
again K62, K123, K315 and also K195 (33). Both stud-
ies found that RelA ubiquitination sites appear to be ex-
tremely promiscuous, as site-directed mutagenesis of either
one or combinations of MS-identified RelA lysines did not
result in any reduction of RelA ubiquitination. In contrast
to above described studies, which used proteasomal inhi-
bition as inducer for RelA ubiquitination, we do see a re-
duction inHERC3-drivenRelA ubiquitinationwhen lysines
195 and 315 are mutated (Supplementary Figure S4B). This
indicates that although similar RelA lysines are targeted
with different stimuli, the preference for certain lysines may
vary. Nevertheless, like observed with proteasomal block-
ade, HERC3 is also likely to induce RelA ubiquitination on
more than the currently identified lysines. First, while RelA
single and double K195 and K315 mutant ubiquitination is
diminished, it is not completely abolished. And second, the
effect of K195 and K315 mutation on RelA transcriptional
recovery is minimal.
The identification and characterization of new media-
tors in the NF-B pathway is important to improve our
knowledge and understanding of mechanisms involved in
inflammation and associated diseases, and may potentially
provide new targets for therapy. We present here two pro-
teins, HERC3 and UBQLN1, which have not been previ-
ously connected with the NF-B pathway. HERC3 regu-
lation of NF-B exhibits two unique features: (i) HERC3
is the only ligase identified to date that mediates ubiquiti-
nation of NF-B before it enters the nucleus. (ii) HERC3
links NF-B ubiquitination with its degradation machin-
ery independent of its own enzymatic activity. UBQLN1
takes part in this regulation by stabilizing the interaction
of HERC3 and the proteasome with NF-B. Future stud-
ies will be directed at identifying additional partners in the
HERC3-UBQLN1-NF-B regulatory module, and at ways
to harness this pathway for potential therapies.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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